Procter & Gamble Health Limited — Investor Meet, 17-06-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Procter & Gamble Health Ltd. reported 9-month sales of Rs. 918 Cr, up 8% YoY, with PAT rising 27% to Rs. 234 Cr, driven by their Integrated Growth Strategy focused on portfolio superiority, productivity, and agility. Neurobion and Evion lead with strong brand equity and innovation, supported by expanded rural and digital reach. The new distributor model is enhancing coverage and retail execution, with Neurobion’s pharmacy reach growing 1.4x over 5 years. Productivity efforts saved Rs. 40 Cr, aiding margin expansion of 200 bps over 5 years. Exports grew 12%, with Sri Lanka business up 30%. Management remains confident in sustained growth through continuous innovation and superior consumer engagement.